drugset / Trial / NCT01024192

Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA

NCT01024192 ↗

Phase 4 Completed 135 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic insomnia at the prescription conditions of daily practice Secondary Objective: To evaluate the satisfaction of the patient with chronic insomnia with Stilnox CR over an as needed basis.

Timeline

Start
2009-11
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ZOLPIDEM SL800750 Unknown 12.5 mg Oral

Indications